Gefitinib in Treating Patients With Cervical Cancer
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Biological therapies such as gefitinib may interfere with the growth of the tumor
cells and slow the growth of cervical cancer. Comparing results of diagnostic procedures
performed before, during, and after treatment with gefitinib may help doctors predict a
patient's response to treatment and help plan the most effective treatment.
PURPOSE: This phase II trial is studying how well gefitinib works in treating patients with
cervical cancer.